deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03018080

Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy)

LCI-BRE-H2N-PEPP-001: A Pilot Study of Paclitaxel Plus Pembrolizumab in Patients With Metastatic HER2-Negative Breast Cancer (The PePPy Trial)

Sponsor: Merck Sharp & Dohme LLC

Conditions Breast - Female Male Breast Cancer
Interventions Paclitaxel Pembrolizumab
Updated 22 times since 2017 Last updated: Jul 26, 2023 Started: Jun 12, 2017 Primary completion: Jul 29, 2021 Completion: Aug 5, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03018080, this PHASE2 trial focuses on Breast - Female and Male Breast Cancer and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 22 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~May 2019 · 5 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Dec 2019 · 6 months · monthly snapshot~Dec 2019 – ~Jun 2020 · 6 months · monthly snapshot~Jun 2020 – ~Dec 2020 · 6 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~May 2022 · 4 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Sep 2023 · 7 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

22 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Feb 2023 — Sep 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Nov 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 17 earlier versions

  1. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

  4. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Dec 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2

  7. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  10. Jun 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  11. Dec 2019 — Jun 2020 [monthly]

    Recruiting PHASE2

  12. Jun 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  13. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  14. Dec 2018 — May 2019 [monthly]

    Recruiting PHASE2

  15. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  16. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  17. Feb 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • Wake Forest University Health Sciences
Data source: Wake Forest University Health Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations